

Katrina Vanura

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3457145/publications.pdf>

Version: 2024-02-01

44
papers

996
citations

471509

17
h-index

454955

30
g-index

44
all docs

44
docs citations

44
times ranked

1929
citing authors

#	ARTICLE	IF	CITATIONS
1	Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders. <i>Cancer Discovery</i> , 2022, 12, 372-387.	9.4	77
2	Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. <i>Blood</i> , 2021, 137, 1365-1376.	1.4	72
3	Sex as decisive variable in lymphoid neoplasms—an update. <i>ESMO Open</i> , 2021, 6, 100001.	4.5	3
4	Core-binding factor leukemia hijacks the T-cell-prone PU.1 antisense promoter. <i>Blood</i> , 2021, 138, 1345-1358.	1.4	12
5	Reply to Comment on “UGT2B17 modifies drug response in chronic lymphocytic leukaemia” <i>British Journal of Cancer</i> , 2020, 123, 1347-1348.	6.4	0
6	UGT2B17 modifies drug response in chronic lymphocytic leukaemia. <i>British Journal of Cancer</i> , 2020, 123, 240-251.	6.4	13
7	Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial. <i>Blood</i> , 2020, 136, 2-4.	1.4	1
8	Core Binding Factor Leukemias Utilize a Physiologic Sense/Antisense Promoter Switch Employed By T-Cells. <i>Blood</i> , 2020, 136, 40-41.	1.4	0
9	Inactivation of Prostaglandin E2 as a Mechanism for UGT2B17-Mediated Adverse Effects in Chronic Lymphocytic Leukemia. <i>Frontiers in Oncology</i> , 2019, 9, 606.	2.8	12
10	Circulating hormones and nuclear hormone receptor expression are associated with treatment-free survival in patients with chronic lymphocytic leukemia. <i>Drug Metabolism and Pharmacokinetics</i> , 2019, 34, S29.	2.2	0
11	Sex-dependent association of circulating sex steroids and pituitary hormones with treatment-free survival in chronic lymphocytic leukemia patients. <i>Annals of Hematology</i> , 2018, 97, 1649-1661.	1.8	12
12	Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy. <i>JCI Insight</i> , 2018, 3, .	5.0	123
13	Abstract 5237: Sex-dependent association of circulating sex steroids, pituitary hormones and treatment-free survival in patients with chronic lymphocytic leukemia. , 2018, , .		0
14	Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition. <i>Leukemia</i> , 2016, 30, 1246-1254.	7.2	66
15	Reappraising Immunoglobulin Repertoire Restrictions in Chronic Lymphocytic Leukemia: Focus on Major Stereotyped Subsets and Closely Related Satellites. <i>Blood</i> , 2016, 128, 4376-4376.	1.4	1
16	Cannabinoid Receptors Are Overexpressed in CLL but of Limited Potential for Therapeutic Exploitation. <i>PLoS ONE</i> , 2016, 11, e0156693.	2.5	11
17	Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas. <i>Medicine (United States)</i> , 2015, 94, e2388.	1.0	24
18	SAR-Guided Development and Characterization of a Potent Antitumor Compound toward B-Cell Neoplasms with No Detectable Cytotoxicity toward Healthy Cells. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 1244-1253.	6.4	5

#	ARTICLE	IF	CITATIONS
19	Lupus anticoagulant and thrombosis in splenic marginal zone lymphoma. <i>Thrombosis Research</i> , 2014, 134, 980-984.	1.7	20
20	The Runx-PU.1 pathway preserves normal and AML/ETO9a leukemic stem cells. <i>Blood</i> , 2014, 124, 2391-2399.	1.4	32
21	Immunoglobulin Heavy Chain (IgH) Knockout Inhibits Proliferation of Pre-BCR+ B-Cell Acute Lymphoblastic Leukemia (B-ALL) Via a FOXO1 and MYC Dependent Mechanism. <i>Blood</i> , 2014, 124, 287-287.	1.4	4
22	Lipoprotein lipase in chronic lymphocytic leukaemia – Strong biomarker with lack of functional significance. <i>Leukemia Research</i> , 2013, 37, 631-636.	0.8	14
23	UDP-glucuronosyltransferase 2B17 genotype and the risk of lung cancer among Austrian Caucasians. <i>Cancer Epidemiology</i> , 2013, 37, 625-628.	1.9	13
24	Overexpression of uridine diphospho glucuronosyltransferase 2B17 in high-risk chronic lymphocytic leukemia. <i>Blood</i> , 2013, 121, 1175-1183.	1.4	48
25	Chronic Lymphocytic Leukemia Patients Have a Preserved Cytomegalovirus-Specific Antibody Response despite Progressive Hypogammaglobulinemia. <i>PLoS ONE</i> , 2013, 8, e78925.	2.5	11
26	Recombinant antibodies encoded by IGHV1-69 react with pUL32, a phosphoprotein of cytomegalovirus and B-cell superantigen. <i>Blood</i> , 2012, 119, 2293-2301.	1.4	48
27	Cannabinoid Receptor 1 in Chronic Lymphocytic Leukemia: Strong Prognostic Marker with Limited Therapeutic Use. <i>Blood</i> , 2012, 120, 4565-4565.	1.4	1
28	Prevalence and clinical impact of autoimmune diseases and chronic infections in malignant lymphomas at diagnosis. <i>Annals of Hematology</i> , 2011, 90, 947-954.	1.8	4
29	Prolonged progression-free survival in patients with chronic lymphocytic leukemia receiving granulocyte colony-stimulating factor during treatment with fludarabine, cyclophosphamide, and rituximab. <i>Annals of Hematology</i> , 2011, 90, 1131-1136.	1.8	12
30	NOTCH2 links protein kinase C delta to the expression of CD23 in chronic lymphocytic leukaemia (CLL) cells. <i>British Journal of Haematology</i> , 2010, 148, 868-878.	2.5	27
31	Sequential gene expression profiling during treatment for identification of predictive markers and novel therapeutic targets in chronic lymphocytic leukemia. <i>Leukemia</i> , 2010, 24, 2122-2127.	7.2	8
32	UDP Glucuronosyltransferase 2B17 Double Deletion Genotype Is An Independent Marker for Poor Prognosis In Multiple Myeloma. <i>Blood</i> , 2010, 116, 2955-2955.	1.4	0
33	Partial Characterization and In Vitro Expansion of Putative CLL Precursor/Stem Cells Which Are Dependent on Bone Marrow Microenvironment for Survival. <i>Blood</i> , 2010, 116, 2433-2433.	1.4	1
34	Expression of Lipoprotein Lipase In Chronic Lymphocytic Leukemia Cells: Is There a Biological Function?. <i>Blood</i> , 2010, 116, 3580-3580.	1.4	0
35	V(D)J targeting mistakes occur at low frequency in acute lymphoblastic leukemia. <i>Genes Chromosomes and Cancer</i> , 2009, 48, 725-736.	2.8	9
36	Relative seroprevalence of human herpes viruses in patients with chronic lymphocytic leukaemia. <i>European Journal of Clinical Investigation</i> , 2009, 39, 497-506.	3.4	27

#	ARTICLE	IF	CITATIONS
37	Gene expression signature of chronic lymphocytic leukaemia with Trisomy 12. <i>European Journal of Clinical Investigation</i> , 2009, 39, 568-575.	3.4	28
38	Autoimmune conditions and chronic infections in chronic lymphocytic leukemia patients at diagnosis are associated with unmutated IgVH genes. <i>Haematologica</i> , 2008, 93, 1912-1916.	3.5	25
39	Effective Targeting of the PI3-K Pathway in CLL with NVP-BEZ235, a Novel Orally Available Dual PI3K/mTOR Inhibitor. <i>Blood</i> , 2008, 112, 3166-3166.	1.4	1
40	In Vivo Reinsertion of Excised Episomes by the V(D)J Recombinase: A Potential Threat to Genomic Stability. <i>PLoS Biology</i> , 2007, 5, e43.	5.6	31
41	Autoimmune or Chronic Infectious Disease in B-CLL at Diagnosis: Association with Unmutated VH Gene Status and Unfavorable Cytogenetics.. <i>Blood</i> , 2007, 110, 3092-3092.	1.4	0
42	Recombinase, chromosomal translocations and lymphoid neoplasia: Targeting mistakes and repair failures. <i>DNA Repair</i> , 2006, 5, 1246-1258.	2.8	90
43	â€œ Candidatus Thiobios zoothamnicoli,â€œ an Ectosymbiotic Bacterium Covering the Giant Marine Ciliate <i>Zoothamnium niveum</i> . <i>Applied and Environmental Microbiology</i> , 2006, 72, 2014-2021.	3.1	84
44	Distinct t(7;9)(q34;q32) breakpoints in healthy individuals and individuals with T-ALL. <i>Nature Genetics</i> , 2003, 33, 342-344.	21.4	26